Inflammatory bowel diseases (IBD) significantly affect millions of people’s quality of life, and most of the patients are diagnosed with IBD under the age of 35. Current therapies for IBD often rely on lifetime drug administration, and are characterized by limited therapeutic effects and inevitable side effects. There is a strong clinical demand for new, effective and safe therapies for IBD. In this project, a targeting oral drug delivery system will be developed at University of Helsinki in collaboration with researchers from Harvard University. Immunomodulatory cytokine will be delivered to elicit the anti-inflammatory effects of macrophages at inflamed mucosa for IBD therapy, which may not only improve therapeutic effects but also reduce systemic side effects.
|Todellinen alku/loppupvm||01/09/2019 → 31/08/2022|